JP2020529850A - カルバペネマーゼを産生性のエンテロバクター目、シュードモナス属、およびアシネトバクター属の種の、色原体を用いる検出 - Google Patents
カルバペネマーゼを産生性のエンテロバクター目、シュードモナス属、およびアシネトバクター属の種の、色原体を用いる検出 Download PDFInfo
- Publication number
- JP2020529850A JP2020529850A JP2020506717A JP2020506717A JP2020529850A JP 2020529850 A JP2020529850 A JP 2020529850A JP 2020506717 A JP2020506717 A JP 2020506717A JP 2020506717 A JP2020506717 A JP 2020506717A JP 2020529850 A JP2020529850 A JP 2020529850A
- Authority
- JP
- Japan
- Prior art keywords
- cephem
- acetamide
- aminothiazole
- methoxyimino
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010068385 carbapenemase Proteins 0.000 title claims abstract description 82
- 241000589516 Pseudomonas Species 0.000 title claims abstract description 58
- 241000589291 Acinetobacter Species 0.000 title claims abstract description 52
- 241000305071 Enterobacterales Species 0.000 title claims abstract description 33
- 241000894007 species Species 0.000 title description 14
- 238000000034 method Methods 0.000 claims abstract description 65
- SKNGHROBOKBHGJ-UHFFFAOYSA-N 2-methoxyiminoacetamide Chemical compound CON=CC(N)=O SKNGHROBOKBHGJ-UHFFFAOYSA-N 0.000 claims abstract description 62
- 150000003839 salts Chemical class 0.000 claims abstract description 57
- 238000012360 testing method Methods 0.000 claims abstract description 45
- 239000012429 reaction media Substances 0.000 claims abstract description 4
- 239000000523 sample Substances 0.000 claims description 67
- 239000003112 inhibitor Substances 0.000 claims description 45
- -1 2,4-dinitrostyryl Chemical group 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 17
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 claims description 13
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 11
- 229960001763 zinc sulfate Drugs 0.000 claims description 10
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 10
- 150000007524 organic acids Chemical class 0.000 claims description 9
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 8
- 102000006635 beta-lactamase Human genes 0.000 claims description 8
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical group OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 8
- 229960003324 clavulanic acid Drugs 0.000 claims description 8
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical group N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims description 8
- 229960003326 cloxacillin Drugs 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 150000003952 β-lactams Chemical class 0.000 claims description 7
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 5
- 125000005504 styryl group Chemical group 0.000 claims description 5
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 3
- 102000002068 Glycopeptides Human genes 0.000 claims description 3
- 108010015899 Glycopeptides Proteins 0.000 claims description 3
- 108010040201 Polymyxins Proteins 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 2
- 239000003880 polar aprotic solvent Substances 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- IKWLIQXIPRUIDU-ZCFIWIBFSA-N (6r)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound OC(=O)C1=CCS[C@@H]2CC(=O)N12 IKWLIQXIPRUIDU-ZCFIWIBFSA-N 0.000 claims 1
- LYZKBEXYJKVGFY-LNUXAPHWSA-N (6R)-4-[2-(2,4-dinitrophenyl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound [N+](=O)([O-])C1=C(C=CC2S[C@H]3N(C(=C2)C(=O)O)C(C3)=O)C=CC(=C1)[N+](=O)[O-] LYZKBEXYJKVGFY-LNUXAPHWSA-N 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 33
- 239000000243 solution Substances 0.000 description 27
- 238000001514 detection method Methods 0.000 description 16
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 239000012085 test solution Substances 0.000 description 11
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 7
- 150000001780 cephalosporins Chemical class 0.000 description 7
- 238000000751 protein extraction Methods 0.000 description 7
- 206010028933 Neonatal diabetes mellitus Diseases 0.000 description 6
- 239000011536 extraction buffer Substances 0.000 description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 229940041011 carbapenems Drugs 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- 235000013902 inosinic acid Nutrition 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 241000588626 Acinetobacter baumannii Species 0.000 description 4
- 108020004256 Beta-lactamase Proteins 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 4
- 241000588914 Enterobacter Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000740455 Klebsiella pneumoniae Metallo-beta-lactamase type 2 Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229940124587 cephalosporin Drugs 0.000 description 4
- 238000002813 epsilometer test Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000003260 vortexing Methods 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101150049515 bla gene Proteins 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- IABBAGAOMDWOCW-UHFFFAOYSA-N Nicametate citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)CCOC(=O)C1=CC=CN=C1 IABBAGAOMDWOCW-UHFFFAOYSA-N 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000001142 dicarboxylic acid group Chemical group 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 108010071437 oxacillinase Proteins 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/10—Enterobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
- C12Y305/02006—Beta-lactamase (3.5.2.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- G01N2333/986—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides (3.5.2), e.g. beta-lactamase (penicillinase, 3.5.2.6), creatinine amidohydrolase (creatininase, EC 3.5.2.10), N-methylhydantoinase (3.5.2.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
Claims (17)
- 試料中の、カルバペネマーゼ産生性のエンテロバクター目、シュードモナス属、およびアシネトバクター属の存在を検出するための方法であって、
カルバペネマーゼ産生性のエンテロバクター目、シュードモナス属、またはアシネトバクター属を含む疑いのある試料を用意すること、
当該試料を、(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩の溶液と反応させること、および
カルバペネマーゼ産生性のエンテロバクター目、シュードモナス属、またはアシネトバクター属が当該試験試料に存在する場合における反応媒体中の色の変化を検出すること、を含む方法。 - 当該試料が生物学的試料である、請求項1に記載の方法。
- 当該生物学的試料が、尿などの生体試料または典型的には分離細胞培養物からなる群から選択される、請求項2に記載の方法。
- 前記方法が、(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩との反応前または反応と同時に、試料を溶解させるステップをさらに含む、請求項1〜3のいずれか一項に記載の方法。
- 当該試料の溶解が、(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩の存在下で起こる、請求項1〜3のいずれか一項に記載の方法。
- 当該試料の溶解が、ポリミキシン、グリコペプチドおよびポリペプチド抗生物質の組合せによって促進される、請求項5に記載の方法。
- 試料の([(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩との反応が、色の変化を観察するのに十分な時間、好ましくは1時間未満、より好ましくは30分未満、最も好ましくは約5〜約20分間、行われる、請求項1〜6のいずれか一項に記載の方法。
- 当該試料の([(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩との反応が、約5℃〜約40℃、より好ましくは約20℃〜約37℃、最も好ましくは35℃の温度で行われる、請求項1〜7のいずれか一項に記載の方法。
- 広域スペクトルβ−ラクタム(ESBL)阻害剤、AmpC阻害剤またはこれらの混合物をさらに含む、前記請求項のいずれか一項に記載の方法。
- ([(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩が、カルバペネムもしくはペネム単独と組み合わせて、または広域スペクトルβ−ラクタム(ESBL)阻害剤、AmpC阻害剤もしくはこれらの混合物と組み合わせて使用される、請求項1〜9のいずれか一項に記載の方法。
- 広域スペクトル阻害剤がクラブラン酸であり、AmpC阻害剤がクロキサシリンまたはその混合物である、請求項9または10に記載の方法。
- 当該阻害剤が、約30μg/ml〜約50μg/mlの濃度のクラブラン酸及び約300μg/ml〜約500μg/mlの濃度のクロキサシリンのうちの少なくとも1つを含む、請求項1〜11のいずれか一項に記載の方法。
- ([(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩が、有機溶媒、有機酸および硫酸亜鉛の少なくとも1種を含む溶液に溶解されている、請求項1〜12のいずれか一項に記載の方法。
- 当該有機溶媒が、極性非プロトン性溶媒、好ましくはDMSOであり、前記有機酸が直鎖状飽和ジカルボン酸である、請求項10に記載の方法。
- ([(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩の、試料中の、カルバペネマーゼ産生性のエンテロバクター目、シュードモナス属、およびアシネトバクター属の存在を検出するための使用。
- ([(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩が、カルバペネムもしくはペネムだけと組み合わせて、または広域スペクトルβ−ラクタム(ESBL)阻害剤、AmpCもしくはこれらの混合物と組み合わせて使用される、請求項15に記載の([(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩の使用。
- 微生物がカルバペネム加水分解性β−ラクタマーゼを産生するかどうかを判定するためのキットであって、
([(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩を含むバイアル、
([(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3−セフェム−4−カルボン酸)またはその塩でコーティングされたウェルを有するマイクロタイタープレート、または
HMRZ−98([(7R)−7−[(z)−2−(2−アミノチアゾール−4−イル)−(Z)−2(メトキシイミノ)アセトアミド]−3−(2,4−ジニトロスチリル)−3− セフェム−4−カルボン酸)またはその塩を含浸させた分析ディスク、および
広域スペクトルβ−ラクタム(ESBL)阻害剤、AmpC阻害剤もしくはこれらの混合物、を含むキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1712671.5A GB201712671D0 (en) | 2017-08-07 | 2017-08-07 | Chromogenic Carbapenemase detection method |
GB1712671.5 | 2017-08-07 | ||
PCT/GB2018/052255 WO2019030519A1 (en) | 2017-08-07 | 2018-08-07 | DETECTION OF PSEUDOMONAS AND ACINETOBACTER SPECIES PRODUCING CARBAPENEMASES USING CHROMOGENES |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020529850A true JP2020529850A (ja) | 2020-10-15 |
JP7411541B2 JP7411541B2 (ja) | 2024-01-11 |
Family
ID=59894936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020506717A Active JP7411541B2 (ja) | 2017-08-07 | 2018-08-07 | カルバペネマーゼを産生性のエンテロバクター目、シュードモナス属、およびアシネトバクター属の種の、色原体を用いる検出 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3665299B1 (ja) |
JP (1) | JP7411541B2 (ja) |
CN (1) | CN111133114B (ja) |
AU (1) | AU2018315240A1 (ja) |
CA (1) | CA3072023A1 (ja) |
ES (1) | ES2900172T3 (ja) |
GB (2) | GB201712671D0 (ja) |
SA (1) | SA520411245B1 (ja) |
WO (1) | WO2019030519A1 (ja) |
ZA (1) | ZA202000674B (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002024707A1 (fr) * | 2000-09-22 | 2002-03-28 | Zenyaku Kogyo Kabushiki Kaisya | Composes cephemes et reactifs de detection de beta-lactamases a large spectre, contenant ces composes |
JP2004166694A (ja) * | 2002-10-29 | 2004-06-17 | Showa Yakuhin Kako Kk | β−ラクタマーゼ検出試薬組成物、検出キット及び検出方法 |
JP2011500057A (ja) * | 2007-10-19 | 2011-01-06 | ベクトン・ディキンソン・アンド・カンパニー | ベータ−ラクタマーゼの検出のための方法および組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003280590A1 (en) * | 2002-10-29 | 2004-05-25 | Hanaki, Hideaki Mr | Beta -lactamase detecting reagent composition, detection kit and detection method |
CN101993910B (zh) * | 2009-08-11 | 2013-01-02 | 湘北威尔曼制药股份有限公司 | 一种β-内酰胺酶的检测方法及检测试纸 |
FR2956866B1 (fr) * | 2010-03-01 | 2014-01-10 | Bio Rad Pasteur | Procede de detection en milieu liquide de bacteries resistantes aux cephalosporines de troisieme generation |
CN103764838B (zh) * | 2011-06-22 | 2018-07-27 | 国家医疗保健研究所 | 用于检测样品中存在产生碳青霉烯酶的细菌的方法 |
GB201520977D0 (en) * | 2015-11-27 | 2016-01-13 | Mast Group Ltd | Carbapenemase-producing bacteria detection method |
-
2017
- 2017-08-07 GB GBGB1712671.5A patent/GB201712671D0/en not_active Ceased
-
2018
- 2018-08-07 CA CA3072023A patent/CA3072023A1/en active Pending
- 2018-08-07 GB GB1812831.4A patent/GB2566810B/en not_active Expired - Fee Related
- 2018-08-07 ES ES18758681T patent/ES2900172T3/es active Active
- 2018-08-07 AU AU2018315240A patent/AU2018315240A1/en active Pending
- 2018-08-07 EP EP18758681.3A patent/EP3665299B1/en active Active
- 2018-08-07 WO PCT/GB2018/052255 patent/WO2019030519A1/en unknown
- 2018-08-07 CN CN201880062349.4A patent/CN111133114B/zh active Active
- 2018-08-07 JP JP2020506717A patent/JP7411541B2/ja active Active
-
2020
- 2020-01-31 ZA ZA2020/00674A patent/ZA202000674B/en unknown
- 2020-02-05 SA SA520411245A patent/SA520411245B1/ar unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002024707A1 (fr) * | 2000-09-22 | 2002-03-28 | Zenyaku Kogyo Kabushiki Kaisya | Composes cephemes et reactifs de detection de beta-lactamases a large spectre, contenant ces composes |
JP2004166694A (ja) * | 2002-10-29 | 2004-06-17 | Showa Yakuhin Kako Kk | β−ラクタマーゼ検出試薬組成物、検出キット及び検出方法 |
JP2011500057A (ja) * | 2007-10-19 | 2011-01-06 | ベクトン・ディキンソン・アンド・カンパニー | ベータ−ラクタマーゼの検出のための方法および組成物 |
Non-Patent Citations (5)
Title |
---|
BROWN, M. R. W. AND WINSLEY, B. E.: "Synergism between polymyxin and polysorbate 80 against Pseudomonas aeruginosa", JOURNAL OF GENERAL MICROBIOLOGY, vol. 68, JPN7022002357, 1971, pages 367 - 373, ISSN: 0005070525 * |
CHAPMAN, D. G. AND RUSSEL A. D.: "Pretreatment wit hcolistin and proteus sensitivity ro other agents", THE JOURNAL OF ANTIBIOTICS, vol. 2, JPN7022002358, 1978, pages 124 - 130, ISSN: 0005070526 * |
HANAKI, H. ET AL.: "The synthesis of 7-substituted-3-dinitrostyryl cephalosporins and their ability fo detecting extende", J. ANTIBIOT., vol. 58(1), JPN7022002356, 2005, pages 69 - 73, XP055526123, ISSN: 0005070524 * |
STORCH, G. A. ET AL.: "Antibiotic-induced lysis of Enterococci", J. CLIN. INVEST., vol. 68, JPN7022002359, 1981, pages 639 - 645, ISSN: 0005070527 * |
VIEDMA, E. ET AL.: "VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, spain", EMERGING INFECTIOUS DISEASES, vol. 18(8), JPN7022002360, 2012, pages 1235 - 1241, ISSN: 0005070528 * |
Also Published As
Publication number | Publication date |
---|---|
EP3665299B1 (en) | 2021-07-21 |
SA520411245B1 (ar) | 2023-01-22 |
GB2566810B (en) | 2021-09-22 |
RU2020103804A3 (ja) | 2021-11-29 |
WO2019030519A1 (en) | 2019-02-14 |
RU2020103804A (ru) | 2021-09-10 |
CN111133114A (zh) | 2020-05-08 |
ES2900172T3 (es) | 2022-03-16 |
EP3665299A1 (en) | 2020-06-17 |
AU2018315240A1 (en) | 2020-02-20 |
GB201712671D0 (en) | 2017-09-20 |
CN111133114B (zh) | 2023-10-27 |
GB2566810A (en) | 2019-03-27 |
GB201812831D0 (en) | 2018-09-19 |
CA3072023A1 (en) | 2019-02-14 |
JP7411541B2 (ja) | 2024-01-11 |
ZA202000674B (en) | 2023-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6101257B2 (ja) | サンプル中のカルバペネマーゼ産生菌の存在を検出するための方法 | |
AlTamimi et al. | Comparison of phenotypic and PCR methods for detection of carbapenemases production by Enterobacteriaceae | |
JP7376625B2 (ja) | 細菌における抗微生物剤耐性を検出するための組成物、方法、システムおよび/またはキット | |
Lee et al. | Carbapenemase-producing Enterobacterales infections: Recent advances in diagnosis and treatment | |
WO2015003047A1 (en) | Method for the rapid determination of susceptibility or resistance of bacteria to antibiotics | |
EP3380631B1 (en) | Carbapenemase detection method | |
JP2014533951A (ja) | 試料中の基質特異性拡張型β−ラクタマーゼ産生細菌の存在を検出するための方法 | |
EP1791971A2 (en) | Device and method for detecting antibiotic-inactivating enzymes | |
Simon et al. | Evaluation of the automated BD Phoenix CPO Detect panel in combination with the β-CARBA assay for detection and classification of carbapenemase-producing Enterobacterales | |
JP7411541B2 (ja) | カルバペネマーゼを産生性のエンテロバクター目、シュードモナス属、およびアシネトバクター属の種の、色原体を用いる検出 | |
RU2776822C2 (ru) | Выявление продуцирующих карбапенемазу видов enterobacteriales, pseudomonas и acinetobacter с применением хромогена | |
JP7166772B2 (ja) | クラスa型カルバペネマーゼ産生菌の検出方法および検出用多ウェルプレート | |
Cutler et al. | Evaluation of a radiometric method for studying bacterial activity in the presence of antimicrobial agents | |
Saleh et al. | Traditional and Molecular Gene Detection (blaIMP-1 and blaIMP) of multi-drug resistant Acinetobacter baumannii | |
Kaji et al. | Rapid detection of bacteria that produce extended-spectrum β-lactamase by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry | |
Abou-Assy et al. | Efficiency of Various Detection Methods for Carbapenem Resistance Gram negative bacteria in King Faisal Medical Complex Hospital, Taif. Saudi Arabia | |
Liu et al. | Rapid Carbapenem Inactivation Method (rCIM): A New Phenotypic Method for Rapidly Detecting Carbapenemase-Producing Enterobacterales | |
Huang et al. | Rapid detection of Ceftazidine/Avibactam sensitivity in carbapenem-resistant Enterobacteriaceae | |
Boghdady et al. | Brief Outline about Biofilm Resistance to Antimicrobials | |
Bourles et al. | Ertapenem Supplemented Selective Media as a New Strategy to Distinguish β-Lactam-Resistant Enterobacterales: Application to Clinical and Wastewater Samples. Antibiotics 2023, 12, 392 | |
US20190120836A1 (en) | Method for classifying microorganisms | |
Tojo et al. | Evaluation of an Automated Rapid Diagnostic Assay for Detection of Gram-Negative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210708 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220517 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230301 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230530 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231016 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231219 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231225 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7411541 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |